Discovery of Nanobodies against Tetramethylenedisulfotetramine by Integrating Next-Generation Sequencing and Moderate Random Mutagenesis
Analytical Chemistry · 2026
DOI: 10.1021/acs.analchem.6c00989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2026. Verfasst von Chenxi Gao und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing 100193, People's …. Hauptthemen laut MEDLINE: Mutagenesis, High-Throughput Nucleotide Sequencing, Single-Domain Antibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Tetramethylenedisulfotetramine (TETS) is a highly neurotoxic rodenticide and a potential terror agent to national security that can cause death within hours. Therefore, antibody-based guidance for timely determination and treatment is urgently demanded. Discovery of antibody against TETS as a hapten molecule remains a highly challenging, since immunized libraries are often recognized chemical linker or carrier epitopes of hapten-protein conjugates, resulting in an exceedingly low frequency of hapten-specific B cells. Here, we proposed a novel integrated strategy combining next-generation sequencing (NGS) and in vitro random mutagenesis, first successfully discovered the TETS-specific nanobodies (Nbs) within 16 days. The workflow began with the antisera evaluation by identification of IgG subclasses, followed by the enrichment of TETS-specific B cells using a fluorescence-activated cell sorter (FACS). Subsequently, these enriched cells were subjected to NGS to discover TETS-specific Nbs. To improve the affinity of Nbs, an error-prone PCR-based random mutagenesis step with an optimized moderate mutation rate was introduced. Through this strategy, we successfully identified the TETS-specific Nb A104, exhibiting a dissociation constant (KD) of 14.9 nM. Sequence analysis revealed distinct amino acid preferences across both the FR and the CDR of Nbs. Notably, inappropriate amino acid substitutions would compromise the affinity of Nbs. Finally, a chemiluminescent ELISA was developed based on the A104, achieving limits of detection (LODs) of 43 μg/L, 64 μg/L, and 101 μg/L for TETS in grain, human plasma, and human urine, respectively. The results demonstrated that this strategy was a feasible, efficient, and robust platform for the discovery of Nbs against haptens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing 100193, People's Republic of China.
- College of Veterinary Medicine, Qingdao Agricultural University, Qingdao 266109, People's Republic of China.
- Key Laboratory of Digital-Intelligence and Dynamic Perception for Food Quality of China Light Industry, Beijing Technology and Business University, Beijing 100048, People's Republic of China.
ORCID-Profile: Kai Wen, Wenbo Yu, Xiao Liang, Zhanhui Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gao, C., Guo, L., Yang, H., Zhang, Y., Yu, X., Wen, K., Yu, W., Liang, X., Shen, J., Pan, Y., & Wang, Z. (2026). Discovery of Nanobodies against Tetramethylenedisulfotetramine by Integrating Next-Generation Sequencing and Moderate Random Mutagenesis. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.6c00989
Vancouver
Gao C, Guo L, Yang H, Zhang Y, Yu X, Wen K, et al. Discovery of Nanobodies against Tetramethylenedisulfotetramine by Integrating Next-Generation Sequencing and Moderate Random Mutagenesis. Analytical Chemistry. 2026. doi:10.1021/acs.analchem.6c00989
BibTeX
@article{Gao2026,
author = {Gao, Chenxi and Guo, Liuchuan and Yang, Huijuan and Zhang, Yingjie and Yu, Xuezhi and Wen, Kai and Yu, Wenbo and Liang, Xiao and Shen, Jianzhong and Pan, Yantong and Wang, Zhanhui},
title = {Discovery of Nanobodies against Tetramethylenedisulfotetramine by Integrating Next-Generation Sequencing and Moderate Random Mutagenesis},
journal = {Analytical Chemistry},
year = {2026},
doi = {10.1021/acs.analchem.6c00989}
}
EUVIMED